HAMBURG, Germany, Aug. 21, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented : "We look forward to our continued collaboration with the Jain Foundation on this project. This collaboration highlights both the increasing role that foundations play in delivering solutions for unmet medical needs and also how Evotec's broad and comprehensive discovery platform can be leveraged in support of these goals in a highly efficient and effective manner."
Dr Plavi Mittal, President and CEO of the Jain Foundation added : "We are excited to be moving toward screening compound libraries with Evotec. This is an important step toward accomplishing our mission of finding a therapy for Limb-girdle muscular dystrophy type 2B /Miyoshi Myopathy (LGMD2B/MM)."No financial details were disclosed. ABOUT THE EVOTEC AND JAIN FOUNDATION COLLABORATION In 2012, Evotec and the Jain foundation initiated a research project to develop a cell-based high throughput screening assay using dysferlin deficient cells. The aim of this project is to develop a simple test for the well-being of a muscle cell in the absence of dysferlin so that compounds that improve the well-being of dysferlin deficient muscle cells can be identified. ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com ABOUT JAIN FOUNDATION The Jain Foundation, located in Bellevue Washington, USA, is a privately funded not-for-profit focused on finding a therapy for muscular dystrophies caused by dysferlin deficiency (LGMD2B/Miyoshi Myopathy).
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV